GlassScriptPhysician profile
Wendy A Waguespack
NPI 1447319058
$4,830.82
in general payments reported to CMS, 2019-2025
23 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $351 · 2021: $799 · 2022: $1,131 · 2023: $707 · 2024: $387 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Entertainment: $17.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.45 |
| Entertainment | $17.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,605.80 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $845.35 | 2019-2025 | Hydrus Microstent, Tryptyr, Precision 1 |
| Allergan, INC. | $445.10 | 2019-2022 | |
| Coopervision INC. | $236.83 | 2019-2025 | Clariti Contact Lens, Biofinity Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $209.72 | 2019-2022 | |
| Genentech USA, INC. | $196.27 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $151.82 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Rxsight INC | $135.83 | 2022 | |
| Biotissue Holdings INC. | $133.52 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $122.57 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $119.22 | 2022-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $117.65 | 2024 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $115.47 | 2019-2020 | |
| Abbvie INC. | $103.90 | 2022-2023 | Lumigan, Vuity |
| Shire North American Group INC | $65.96 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $52.39 | 2024 | Oxervate |
| Vanda Pharmaceuticals INC. | $43.94 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $29.52 | 2019 | |
| Kala Pharmaceuticals, INC. | $25.43 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.80 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Optos, INC. | $17.01 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $16.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Waguespack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.